Podcasts about pharmaceutical

Andrea Stricker discusses reports that the Iranian regime used illicit chemicals and pharmaceutical-based agents to debilitate protesters during recent, highly lethal national unrest. 9.1610

The Pennsylvania Gaming Control Board is reporting a significant increase in revenue from all forms of gaming during January 2026. Central Pa.-area casinos helped contribute to the gains. Pharmaceutical giant Johnson & Johnson recently announced plans to build a new cell therapy manufacturing plant in the greater Philadelphia region. The state will contribute more than $41 million towards the project in tax credits and grants. More than a dozen Harrisburg residents are displaced after fire swept through six rowhomes early Sunday morning. A York County woman is dead after driving the wrong way on Route 283 in Lancaster County Saturday night. State and local officials say they're worried about the impact an ICE detention center could have upon Schuylkill and Berks counties' rural infrastructure, such as its water and sewer systems, as well as EMS departments. And a deep dive: Electric bills in Pennsylvania and elsewhere have been rising faster than the rate of inflation. In his recent budget address, Governor Josh Shapiro blamed the sudden increase on an organization called P-J-M. What is it, and how does it affect your bills? Did you know that if every sustaining circle member gives as little as $12 more a month, we'd close the gap caused by federal funding cuts? Increase your gift at https://witf.org/increase or become a new sustaining member at www.witf.org/givenow. And thanks!Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

Pharmaceutical packaging is undergoing rapid transformation as connectivity, sustainability, automation, and evolving regulatory demands reshape how medicines are protected, tracked, and delivered. From smart packaging features and prefilled injectables to e-commerce fulfillment and digital compliance systems, packaging and equipment investment decisions are increasingly tied to flexibility, data visibility, and long-term modernization. In this episode of Off Script, we spoke with Rebecca Marquez, director of custom research at PMMI, about the association's latest Trends and Challenges in Pharmaceutical Manufacturing white paper. The conversation explores how connected packaging technologies are strengthening relationships between manufacturers, regulators, and patients; why sustainability initiatives are advancing despite material performance and validation challenges; and how growth in biologics and prefilled injectables is driving new packaging and equipment demands. Marquez also breaks down the regulatory documentation gap between OEMs and end users, the rise of automation technologies, and more.

Gregory Zuckerman details Gail Smith's insect-based vaccine technology at Novavax and discusses how major pharmaceutical giants like Merck initially hesitated to join the pandemic race. 4

Timestamps00:06 - Live stream with Liz discussing her new stylish headphones.01:56 - YouTube's changing algorithms impact subscriber counts and content quality.05:49 - Quick diagnosis leads to unnecessary statin prescription without proper testing.07:52 - Pharmaceutical trust can lead to misunderstandings about health issues.11:31 - Discussion on creating alternative food resembling traditional dishes.13:35 - Struggling with diet consistency requires reliable fallback options.17:18 - Discussion on dragon fruit and its carbohydrate content in a carnivore diet.19:09 - Carnivore diet may reduce inflammation, but supplements can still be beneficial for some individuals.22:34 - Patient experiences unusual reactions related to amoxicillin and hearing loss.24:13 - Discussion on the complexities of steroid and antibiotic usage in medical treatment.27:44 - Recognizing the importance of mistakes for personal and professional growth.29:30 - Learning from dietary mistakes can improve future choices.32:34 - Carnivore diet simplifies meal preparation and reduces food-related stress.34:18 - Discussion on the impact of GLP1 drugs and faith in pharmaceutical practices.37:49 - Study lacks proof on patient leaflet reading impacting drug side effect claims.39:49 - Public awareness is challenging pharmaceutical industry's narrative.43:12 - Drug companies often underreport side effects of medications.45:08 - Tips for cooking and storing meats more effectively.48:38 - Concerns about cholesterol levels and CAC scores require more detailed health information.50:34 - Understanding baseline health metrics is crucial for interpreting dietary changes.53:53 - Contextual understanding is essential for evaluating health issues.55:52 - Food labelling often misleads consumers about ingredients.59:24 - Discussion on channel updates and audience engagement strategies.

In this bonus episode of Medication Talk, join us as we revisit our Notable New Meds of 2025 webinar and highlight two medications that didn't make it into the main podcast—both newly approved antibiotics with important implications for clinical practice.Listen in as our editors take a deeper look at:Gepotidacin (Blujepa) for uncomplicated urinary tract infectionsAztreonam/avibactam (Emblaveo) for complicated intraabdominal‑abdominal infectionsYou'll hear practical insights into where these therapies fit in current treatment approaches, what safety and interaction issues to watch for, and why they matter when resistance limits your options—giving you more confidence when either of these new meds show up in your practice.**No CE Credit is available for this bonus episode.**Use code mt1026 at checkout for 10% off a new or upgraded subscription.******TRC Healthcare Editors: Sara Klockars, PharmD, BCPSStephen Small, PharmD, BCPS, BCPPS, BCCCP, CNSC None of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in December 2025. The clinical resources related to this podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: Chart: Urinary Tract InfectionsChart: Aztreonam-avibactam (Emblaveo)Article: Keep Boosting Antibiotic Stewardship for Complicated UTIsSend a text*****

The Target List reunion is here

Can a centuries-old cannabis culture survive legalization?In this exclusive episode, Reefer MEDness shares a rare anonymous interview with a SOMACAN quality manager inside Morocco's emerging legal cannabis industry. Kirk and Mr. Anonymous share a car ride through the Rif Mountains and Mr. Anonymous reveals how local farmers are transitioning from black-market hash production into regulated medical cannabis cooperatives producing hundreds of tons of biomass annually.Discover how Morocco's ancient Beldia landrace strain—grown for centuries—is now facing threats from modernization, imported genetics, and pharmaceutical regulation. Learn how CBD and limited THC legalization is reshaping cannabis exports, farmer livelihoods, and global supply chains.From secrecy and stigma to pharmaceutical extraction and international markets, this episode reveals the real human and scientific story behind cannabis legalization in Morocco.Listen now to understand how one of the world's oldest cannabis traditions is adapting to the future of medicine.Transcripts, papers and so much more at: reefermed.ca

When Terry Pirovolakis learned his son had an ultra-rare neurodegenerative disease, SPG50, he refused to accept “no options.” What started as a desperate search for hope became Elpida Therapeutics, a nonprofit driving gene therapy innovation for multiple rare diseases. In this episode, Terry shares the remarkable journey from diagnosis to clinical trials, the power of partnerships, and why urgency matters when every day counts.Show NotesFrom Mystery to Medicine: The Science Behind a Mother's Search | PodcastTaking a Customized and Collaborative Approach to Therapeutic Development | PodcastRare Disease Research for Drug Development | Charles RiverRare Disease | Charles RiverDiscovery | Charles RiverBeyond The Diagnosis

Biopharmaceutical innovation is advancing at an unprecedented pace, yet many patients still face barriers to accessing new medicines. In this episode of Health Matters, John O’Brien, president and CEO of the National Pharmaceutical Council, speaks with Kristin Cahill about why policy, pricing and benefit design are increasingly shaping whether innovation reaches patients. O’Brien shares insights from his career spanning pharmaceutical companies, health plans and government, including his time as a senior drug pricing advisor during the first Trump administration. He explains why prescription drugs remain a focal point in cost debates, what policymakers often misunderstand about value, and how middlemen and misaligned incentives affect what patients pay at the pharmacy counter. The conversation also examines emerging approaches such as direct-to-patient models, most-favored-nation pricing and the early effects of the Inflation Reduction Act, highlighting potential benefits as well as risks to access and future innovation. For healthcare professionals, payers and marketers seeking clarity in a complex policy environment, this episode offers a grounded perspective on how to ensure medical breakthroughs translate into meaningful patient benefit. Listen to the full interview.See omnystudio.com/listener for privacy information.

Calcium supplements are everywhere—but do they actually help your bones? In this episode, we unpack the "calcium conundrum" and challenge the common belief that more supplements automatically mean stronger bones. You'll learn why food-based calcium behaves very differently in the body than pharmaceutical calcium supplements, why most studies show little to no benefit of supplements for adult bone health, and how supplements may even carry unexpected health risks. We focus especially on bone health in adults and postmenopausal women, while emphasizing practical, food-first strategies that actually support long-term health. If you're concerned about osteoporosis, fractures, or bone density—and want to make informed, evidence-based choices—this episode will help you rethink calcium from the ground up. Learn why food, not pills, should be your foundation for bone health. Subscribe for more conversations on nutrition, disease prevention, and putting the power of health back in your hands. Key Takeaways Calcium supplements ≠ food calcium Pharmaceutical calcium is metabolized differently and does not offer the same benefits as calcium from whole foods. Most adult studies show supplements don't prevent fractures In typical adult populations, calcium supplements generally fail to improve bone density or reduce fracture risk. Food sources of calcium are safer and more effective Calcium-rich foods support bone health without the cardiovascular, kidney stone, or other risks linked to supplements. Absorption matters more than intake Only 10–50% of dietary calcium is absorbed, depending on diet quality, gut health, medications, activity level, and overall lifestyle. Postmenopausal bone loss isn't just about calcium Bone loss during this stage appears to be largely unrelated to calcium intake alone. Dairy and non-dairy options make adequacy achievable It's not hard to reach ~800–1200 mg/day from food alone, even without supplements. Cultured dairy is preferred Yogurt, kefir, and aged cheeses provide calcium plus beneficial cofactors like protein, vitamin K, and healthy fats. Fortified foods aren't the same as real food Calcium-fortified products still deliver industrial calcium, not naturally integrated nutrients. Supplements can distract from better nutrition Relying on pills may pull focus (and money) away from improving overall diet quality. Bottom line: think food first Your body knows how to handle real food—bone health starts there. This episode is a call to lead your own healthcare journey with humility, curiosity, and intention—so you can make decisions that truly align with your values and goals. Get your copy of Good Food Great Medicine, 4th ed.: https://a.co/d/1D6hIYM   More references can be found at www.GreatMed.org   Would you like Dr. Hassell to answer your question on the air? Contact us! Write us a letter, We love to hear from you! Send questions, comments, and support to:   Phone/text: 503-773-0770 e-mail: info@GreatMed.org   EIN: 88-326-7056   GreatMed.org 4804 NW Bethany Blvd., Suite I-2, #273 Portland OR 97229   This podcast is sponsored by our generous listeners. #wellness #podcast #wellnessforlife #lifestyle #healthandwellnessgoals  

Mark Cuban, entrepreneur, investor, and cofounder of the Mark Cuban Cost Plus Drug Company, joins JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, to discuss the role of pharmacy benefit managers, insurance formularies, and opaque pricing practices that shape how most Americans access prescription drugs. Hear why he thinks doctors are the good guys in a broken system. Related Content: Pharmaceutical Pricing—JAMA Talks With Mark Cuban

Can Morocco's famous hash industry survive pharmaceutical regulation?In Part 2 of Episode 166, Trevor and Kirk continue their conversation with Jan van Weenen, a European cannabis veteran helping transform Morocco's ancient hash market into a GMP-compliant pharmaceutical industry. From heavy metals in Rif Mountain soil to pricing battles between farmers, co-ops, and manufacturers, this episode reveals the real-world challenges of global cannabis regulation.Jan shares his strategy to build a pharmaceutical cannabis brand now — and pivot into recreational markets later — while navigating European standards, extract distribution, and international licensing.Listen now to explore the birth of Morocco's legal cannabis industry and what it means for Europe and beyond.Jan van Ween - LinkedInTranscripts, papers and so much more at: reefermed.ca

By 2028, SGS CDMO Solutions' MHRA and FDA-inspected site in Wales will operate entirely without paper. For biotech and Pharmaceutical sponsors, this provides a better way to run development and manufacturing projects.“If it can't be done digitally, then we don't want to do it,” says Paul Broomhead, Head of Site. The result is a digitally native CDMO where data, processes, and decisions live in one.Paul Broomhead, Head of Site at SGS CDMO Solutions in Wales, is leading an ambitious digital transformation. In this exclusive interview, Paul reveals why SGS is making a commitment to digital infrastructure, how the transformation creates competitive advantages for biotech sponsors, and what “digitally native” manufacturing actually means in practice for pharmaceutical development and commercialization.Read more

Learn more about your ad choices. Visit megaphone.fm/adchoices

Inside Morocco's cannabis industry: pharmaceutical standards, heavy metals, GACP/GMP hurdles, and why legal cannabis isn't always legitimate.

What happens when a rare disease diagnosis turns life upside down? In this episode of Sounds of Science, host Mary Parker sits down with Bo Bigelow, Amber Freed, and David Fischer to explore the breakthroughs, challenges, and human stories behind Hao-Fountain Syndrome. From a father's fight for his daughter Tess to cutting-edge drug repurposing screens, discover how science, advocacy, and community are rewriting the future for families worldwide. Show NotesRare Disease | Charles River Vital Science Podcast: Strength in Numbers Rare Disease Research for Drug Development Foundation for USP-7 Related Diseases Stronger Every Day Podcast 

Listen in as our editors discuss several novel drugs approved in 2025, including two new eye drops, a new topical for chronic hand eczema, and an oral nonhormonal option for patients with menopausal hot flashes. They'll review efficacy, safety, and considerations for use with these new treatment options.Aceclidine 1.44% Drops (Vizz) for PresbyopiaAcoltremon 0.003% Drops (Tryptyr) for Dry EyeDelgocitinib (Anzupgo) 2% Cream for Chronic Hand EczemaElinzanetant (Lynkuet) for Hot FlashesUse code mt1026 at checkout for 10% off a new or upgraded subscription.******TRC Healthcare Editors: Sara Klockars, PharmD, BCPSStephen Small, PharmD, BCPS, BCPPS, BCCCP, CNSC ******This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in December 2025.******CE Information:None of the speakers have anything to disclose. TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim Credit******The clinical resources related to this podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: Article: Have Treatment Options in Sight for Dry Eye DiseaseChart: Treatments for Dry EyesChart: Managing EczemaArticle: Elinzanetant: Emerging Therapy for Menopausal Hot FlashesChart: Managing Vasomotor Menopause SymptomsFAQ: Managing Genitourinary Menopausal SymptomsChart: Menopausal Hormone TherapiesSend us a textEmail us: ContactUs@trchealthcare.com. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. Learn more about our product offerings at trchealthcare.com.

Over 100,000 Americans die from overdoses every year. Relapse rates run 40-90%. The treatment model hasn't fundamentally changed since the 1970s. And yet the addiction treatment industry is worth $42 billion. Tonight on Hidden Killers Live, we're asking the question the industry doesn't want answered: is failure profitable? Is someone actively benefiting from keeping this system broken?Psychotherapist Shavaun Scott returns for Part 2 of our examination following the Nick Reiner tragedy. The Reiner family had every resource available and it still wasn't enough to save Rob and Michele Reiner. So we're following the money. Every relapse is another admission, another billing cycle. Insurance companies control treatment length through utilization review, overriding doctors. There's no standardized outcome tracking — families can't comparison shop for effectiveness because that data simply doesn't exist.We examine who fights reform when it's proposed. Treatment industry lobbyists. Insurance companies. Pharmaceutical interests. The research on what works is clear: longer treatment, integrated mental health care, medication-assisted treatment. So what's blocking evidence-based care from becoming standard practice? Is this regulatory capture — the industry shaping rules to protect itself? Or is the treatment industrial complex so entrenched that meaningful change is impossible? Join us live for an unflinching look at who profits from broken promises.#NickReiner #RobReiner #AddictionIndustry #TreatmentProfits #RehabReform #ShavaunScott #InsuranceScam #OpioidCrisis #HealthcareFraud #HiddenKillersLiveJoin Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspodInstagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/tonybpodListen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.

From climate change forecasts to cancer drug development, some of the world's biggest institutions rely on computer simulation models to predict outcomes. Governments use climate models to project future temperature changes, sea levels, and extreme weather patterns. Pharmaceutical companies use biological and molecular computer simulations to test their drugs.If our most important forecasts are coming from computer simulations… what does that say about the reality we're living in? Listen to full discussion here: https://www.youtube.com/live/LuVYTsevsfk?si=_9zNgfVkV4Up1o5l

Never miss another webinar! Sign up here: https://imahealth.org/weekly-webinars Mental health care is undergoing a necessary rethink, led in part by physicians like Dr. Josef Witt-Doerring. In this episode of the IMA Weekly Show, Dr. Ryan Cole is joined by psychiatrist Dr. Josef Witt-Doerring, both IMA Senior Fellows, for an in-depth discussion on the forces shaping modern mental health care and what that means for patients moving forward.They explore pharmaceutical involvement in mental health guidelines, ethical concerns surrounding informed consent, and the effects of screen time and emerging AI-based mental health tools. The conversation also addresses seasonal depression and mental health struggles common during winter months.This episode covered:• Pharmaceutical influence on psychiatric guidelines• Informed consent and patient-centered mental health care• The impact of screen time on mental health• AI-driven mental health tools and ethical considerations• Seasonal depression and mental health challengesAlso:• Donate: https://imahealth.org/donate/• Follow: https://imahealth.org/contact/• Webinar: https://imahealth.org/category/weekly-webinars/• Treatment: https://imahealth.org/treatment-protocols/• Medical Disclaimer: https://imahealth.org/about/terms-and-conditions/About IMA (Formerly FLCCC Alliance)The Independent Medical Alliance™ is a nonprofit, 501(c)(3) organization and coalition of physicians, nurses, and healthcare professionals united by a mission to restore trust and transparency in healthcare. The organization's mission is one driven by Honest Medicine™ that prioritizes patients above profits and emphasizes long-term wellness and disease prevention through empowerment of both physicians and their patients. With a focus on evidence-based medicine, informed consent, and systemic reform, IMA is driving a movement to create a more compassionate and effective healthcare system.For more information about the Independent Medical Alliance, visit www.IMAhealth.org

From Trinidad to a $200K Career in Texas: How Kanika Bhagan Mastered the U.S. Medical Sales Market.Can you move to a brand-new country and double your income in less than a year? In this episode of Medical Sales U, Kanika Bhagan reveals the exact strategy she used to transition 17 years of experience from the Caribbean to landing a $200,000 role in the competitive Dallas, Texas market.Kanika's journey is a masterclass in career reinvention. Despite having nearly two decades of experience with giants like Sanofi and AstraZeneca, she faced the "overwhelming" challenge of a new culture and a new market. She shares how she stayed consistent—applying for jobs at 4:00 AM—and why maintaining a "solid reputation" is the most valuable currency in Medical Sales.Watch to learn:The "Business Plan" secret that seasoned veterans often miss.How to network on LinkedIn without getting ghosted.Why a "No" from a hiring manager might actually be your next big lead.Timestamps0:00 - Introduction: Meet Kanika Bhagan0:27 - From $95k to $200k: The Power of Investing in Yourself1:45 - Moving from Trinidad to Dallas: Overcoming the Fear of the Unknown3:12 - The Reality of Networking in the Texas Med-Sales Market5:42 - Why Your Resume Isn't Enough: The Business Plan Strategy7:45 - Using AI to Research Products & Competition9:30 - LinkedIn Secrets: How to Reach Out Without Being "Salesy"12:15 - Breaking In via Contract Work (IQVIA & Abbott)14:05 - How to Turn a Job Rejection into a Future Referral18:40 - Resilience & Professionalism: Advice for Seasoned Pros24:30 - Tips for Moving to a Brand New Market28:00 - Why Dallas is the Ultimate City for FamiliesConnect with Kanika Bhagan on LinkedIn: https://www.linkedin.com/in/kanika-ramkissoon/READY TO BREAK INTO MEDICAL SALES? We help professionals transition into top-tier medical sales roles: medicalsalesu.com/#MedicalSales #MedicalDeviceSales #CareerTransition #PharmaceuticalSales #DallasJobs #NetworkingTips #MedicalSalesYou #JobInterviewStrategy

The crime is not having type 2 diabetes. The crime is that conventional forces in healthcare essentially turn a blind eye to all the ways available to NOT be a type 2 diabetic. Pharmaceutical executives throw lavish parties to celebrate the huge revenues that derive from diabetes drugs that now include the awful GLP-1 agonists, while almost no one in healthcare shows people how to not be diabetic--THAT's the crime. Support the showYouTube channel: https://www.youtube.com/@WilliamDavisMD Blog: WilliamDavisMD.com Membership website for two-way Zoom group meetings: InnerCircle.DrDavisInfiniteHealth.com Books: Super Gut: The 4-Week Plan to Reprogram Your Microbiome, Restore Health, and Lose Weight Wheat Belly: Lose the Wheat, Lose the Weight and Find Your Path Back to Health; revised & expanded ed

In this radio golden oldie from September 4, 2007, Savage exposes the pharmaceutical-industrial complex and the blight of hippie culture. He criticizes the hypocrisy of politicians, both Democrats and Republicans, highlighting their involvement in earmark spending and corruption. He warns against the overmedication of children and the pharmaceutical industry's pursuit of profit. He then mocks the glorification of the aging hippies and how they harmed society.

In this bonus episode of Medication Talk, join us for an extended conversation with our expert panel as we go beyond the original webinar and podcast episode to share brand-new insights and never-before-heard content.Listen in as we dive deeper into practical strategies for starting conversations with patients about tobacco use, plus additional perspectives on nicotine's effects and health risks, emerging therapies, non-drug approaches, and how to make smoking cessation part of everyday pharmacy practice.**No CE Credit is available for this bonus episode.**Special guest:Robin Corelli, PharmD, CTTS, FCSHPProfessor of Clinical PharmacySchool of PharmacyUniversity of California, San FranciscoYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLMClinical Associate Professor of Family MedicinePrisma Health/USC-SOMG Family Medicine Residency ProgramUSC School of Medicine GreenvilleCraig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in November 2025. Plus, it includes brand-new insights and never-before-heard content.The clinical resources related to this podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: Chart: Smoking Cessation Drug TherapyFAQ: E-Cigarettes and VapingArticle: Help Patients Send Their Vaping Habits Up in SmokeUse code mt1026 at checkout for 10% off a new or upgraded subscription.Send us a textEmail us: ContactUs@trchealthcare.com. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. Learn more about our product offerings at trchealthcare.com.

Pharmaceutical company Apnimed said its pill, AD109, is a simple-to-use once-daily oral drug that could "expand and reshape the treatment landscape." Armed with findings from critical phase 3 clinical trials, the company said within months, it's set to submit the pill for a New Drug Application with the Food and Drug Administration. Covering hundreds of studies on digital media and health effects over the last 20 years, the review’s findings mark a departure from previous thoughts on screen use. Please Like, Comment and Follow 'Philip Teresi on KMJ' on all platforms: --- Philip Teresi on KMJ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. -- Philip Teresi on KMJ Weekdays 2-6 PM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Website | Facebook | Instagram | X | Podcast | Amazon | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

When Patricia Weltin's daughters were diagnosed with Ehlers-Danlos Syndrome after years of uncertainty, she turned her frustration into a global movement. In this episode of Sounds of Science, Patricia shares the story behind Beyond the Diagnosis, a powerful art and advocacy initiative that uses portraiture to humanize rare diseases and inspire empathy in medical professionals, students, and communities around the world. From medical schools to courthouses and even Parisian galleries, the traveling exhibit is reshaping how we see children with rare diseases—not as diagnoses, but as vibrant individuals with stories worth telling. Tune in to hear how Patricia's mission is bridging the gap between science and compassion, and how you can help carry it forward.Show NotesFrom Mystery to Medicine: The Science Behind a Mother's Search | PodcastTaking a Customized and Collaborative Approach to Therapeutic Development | PodcastRare Disease Research for Drug Development | Charles RiverRare Disease | Charles RiverDiscovery | Charles RiverBeyond The Diagnosis

Generative AI is moving fast—and in pharma, it's no longer just a buzzword. In this episode of The Effective Statistician Podcast, I speak with Manuel Cossio about how Generative AI is already being applied in real-world pharma settings, where it's delivering value today, and what still needs careful consideration in regulated environments. Manuel brings a unique hybrid background, combining molecular biology, genetics, pharma experience, and deep AI engineering expertise. He works at the cutting edge of AI in clinical development, including agentic systems, human-in-the-loop approaches, and large-scale document automation. This conversation goes well beyond theory. We focus on practical use cases, real limitations, and how statisticians, programmers, and data scientists can responsibly use GenAI to become more effective.

CurifyLabs expands its pharmaceutical technology from Jacksonville to the United States, offering automation solutions that streamline medication preparation for pharmacies and healthcare providers. The technology aims to reduce errors, improve workflow efficiency, and support personalized medicine. CurifyLabs' solutions help healthcare organizations meet regulatory requirements and adapt to evolving industry needs, with anticipated benefits including increased medication accuracy, patient safety, and potential cost savings.Learn more on this news by visiting us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.

Pharmaceuticals are a central—and costly—element of the US health care system. Aaron S. Kesselheim, MD, JD, MPH, of Brigham and Women's Hospital joins JAMA Health Forum Editor in Chief Sandro Galea, MD, DrPH, to discuss the challenge and opportunity of delivering affordable drugs to as many people as possible. Related Content: In Search of Pharmaceutical Policy Innovation in the US

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant events and trends reshaping the industry landscape as we approach 2026. The pharmaceutical and biotech sectors are navigating a transformative period marked by scientific advancements, evolving regulatory frameworks, and strategic partnerships.Starting with a shift towards bolstering drug pipelines, mergers and acquisitions (M&A) have gained momentum. In 2025, this trend was largely fueled by impending patent expirations and an optimistic investment climate within biotech. Pharmaceutical companies are strategically pursuing these opportunities to enhance their innovation capabilities, positioning themselves effectively against competitive pressures. AbbVie's recent $5.6 billion agreement with RemeGen is a testament to this strategy. By entering the PD-1xVEGF bispecific antibody market, AbbVie aims to establish a foothold in a promising area of cancer therapeutics. This investment highlights the growing interest in bispecific antibodies due to their dual-targeting potential, offering enhanced treatment efficacy by simultaneously addressing two cancer pathways.Meanwhile, Eli Lilly's collaboration with Nvidia demonstrates the increasing integration of artificial intelligence (AI) in drug discovery. Their $1 billion co-innovation lab investment aims to harness AI technologies to accelerate new therapy development and refine precision medicine approaches. This partnership exemplifies the transformative potential of AI in optimizing research productivity across the industry.On the regulatory front, Atara Biotherapeutics and Pierre Fabre Pharmaceuticals faced challenges with their EBVallo product. The FDA's repeated rejection of this product underscores the intricate regulatory landscape biopharmaceutical companies must navigate. This situation highlights the necessity for clear communication between industry players and regulatory bodies to ensure innovative therapies reach patients needing them most.In clinical development, Bristol Myers Squibb's Camzyos is set for expansion following successful trials in adolescent patients with cardiomyopathy. This advancement signifies a crucial step towards making advanced therapies available to broader patient demographics, potentially transforming cardiology care.Investment in infrastructure remains a priority as AbbVie announces a $175 million development of a new drug-device plant in Arizona. This move aligns with their broader commitment to invest $10 billion into U.S. operations by 2035, underlining the importance of enhancing manufacturing capabilities and securing supply chains in a globalized market.Additionally, Teva's financial maneuvering with Royalty Pharma illustrates how biopharma firms support clinical advancements through strategic funding partnerships. By securing up to $500 million for its vitiligo drug development, Teva highlights the critical role of financial collaborations in advancing therapeutic innovations.All these developments occur amid concerns about potential governmental threats to scientific integrity within the U.S. biotech industry. Flagship Pioneering's CEO warns that policy changes could undermine fundamental scientific principles, potentially hindering innovation and progress within the sector.As we transition into 2026, there's renewed optimism within biopharma driven by increased investor interest and robust R&D initiatives. This resurgence is expected to be a focal point at upcoming conferences like JPM26, where discussions on policy and political influences on drug pricing will be pivotal.In oncology, Merck & Co.'s rumored acquisition of Revolution Medicines could signal an aggressive expansion of its oncology portfolio. This potential transaction would underscore Merck's strategic focus on small moleSupport the show

In this episode of Disruption/Interruption, host KJ sits down with Jurek Kozyra, founder and CEO of Nanovery, to explore how DNA nanotechnology and AI are revolutionizing molecular medicine. Discover how tiny nanorobots made from DNA could dramatically accelerate drug development, make diagnostics faster and more affordable, and potentially cure diseases that were previously untreatable. From detecting diseases in hours instead of days to cutting years off the drug development process, this conversation reveals the cutting-edge science that's transforming healthcare. Four Key Takeaways: The Promise of Oligonucleotide Therapeutics (9:06) Traditional medicine targets defective proteins, but many diseases can't be cured because we can't find the right molecule. Oligonucleotide therapeutics target mRNA—the underlying mechanism of disease—meaning you could potentially cure all diseases since all proteins come from mRNA. DNA Nanorobots for Rapid Detection (14:12) Nanovery's DNA nanorobots can detect diseases in blood samples within 2-4 hours compared to traditional lab tests that take two days. These self-assembling machines produce fluorescent signals when they find specific DNA or RNA molecules, enabling point-of-care diagnostics. Accelerating Drug Development (17:13) Pharmaceutical companies race against 20-year patents while drugs take 10+ years to develop. Nanovery's technology provides more accurate data at lower cost and time, potentially shaving years off the development process and helping more drugs successfully reach the market. Real-World Clinical Validation (20:26) In a hospital study with 170 patient samples, Nanovery's technology delivered same or better results than traditional tests in just two hours instead of two days—a game-changer for emergency situations like drug overdoses where immediate answers are critical. Quote of the Show (9:05):"If you can target mRNA very specifically, that means that in theory you could potentially cure all diseases. That's why this area is so exciting right now." – Jurek Kozyra Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Jurek Kozyra: LinkedIn: https://www.linkedin.com/in/j3ny/ Company Website: https://nanovery.co.uk How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

Episode Synopsis:Can we trust the medical experts, or has the medical industrial complex been designed to sacrifice our health on the altar of profit and control for the satanic elite?We talk about this and much more, including:What info does Dr. Tenpenny's new book cover?What is the evidence that hygiene has been more effective than mass vaccination?Did people really become magnetic after taking the COVID Jab?How has the current state of our Public Health been orchestrated?What other options besides mandated vaccines do we have to protect our communities?Original Air DateJanuary 7th, 2026Special GuestDr. Sherri Tenpenny – find her at drtenpenny.com, and Dr. Tenpenny's SubstackShow HostsJason Spears & Christopher DeanOur PatreonConsider joining our Patreon Squad and becoming a Tier Operator to help support the show and get access to exclusive content like:Links and ResourcesStudio NotesA monthly Zoom call with Jason and Christopher And More…ORP ApparelMerch StoreConnect With UsLetsTalk@ORPpodcast.comFacebookInstagram

Happy New Year from all of us at Wolf Greenfield.In this episode of IP Talk with Wolf Greenfield, we take our annual look back at the year just concluded and ahead to the new year, 2026, just begun.  From anticipated activity, such as the forward march of artificial intelligence (AI) to unexpected developments, most prominently the new procedures at the PTAB, it was an eventful year.  Here are a few highlights from the conversation:00:53 - Scott McKeown discusses the new administration's impact on the PTAB 02:55 - Ed Russavage offers suggestions for dealing with the backlog of patent applications waiting for examination at the USPTO 03:58 - Christina Licursi on the growth of artificial intelligence04:54 - Dan Young believes strong, creative claiming strategies are critically important in today's environment06:39 - In the Pharmaceutical industry, Jonathan B. Roses sees the potential for easier treatment of diagnostic method claims in 2026 08:27 - Zach Piccolomini on the evolving landscape for standard essential patents 09:52 - Greg Corbett provides a summary of the factors that may result in an increase in litigation in 202610:39 - Christina Licursi sees AI's impact on law firms and clients growing throughout 2026 and in the years beyond

As we all learned in 2020, getting ahead of the next major pandemic is a matter of global concern. For the Coalition for Epidemic Preparedness Innovations, or CEPI (cepi.net), it is their reason for existing. Joining me for this conversation are Valentina Bernasconi, Head of Laboratory Science for CEPI, and Marie-Eve Poupart, Lead Scientist In Charles River's Immunology department. Together we discuss CEPI's progress so far, how Charles River is contributing to the cause, and how we can plan for the unknown Disease X while simultaneously handling current outbreaks of deadly diseases like Ebola, Marburg, Nipah virus, Lassa Fever, and chikungunya.

How do you go from being the Ohio State University mascot to an ICU Nurse, and finally to a top-tier Pharmaceutical Sales Rep at Pfizer in just 11 weeks?In this episode of Medical Sales U, I sit down with Corey Stewart to break down his incredible career transition.- The "Hospital Cafeteria" Interview: The insane story of how Corey interviewed for Pfizer while his wife was in labor (and still crushed it).- The STAR Method: Watch a live roleplay of how to answer the "Tell me about a time..." question using courage and clinical experience.- Salary Negotiation: Full transparency on the numbers. See how Corey negotiated a $112k offer up to a $158k total first-year package.-Networking Strategy: Why reaching out to the team is more important than reaching out to the manager.If you are a nurse, teacher, or athlete looking to break into Medical Device or Pharma Sales, this will give you some insight.CHAPTERS0:00 - Intro: Meeting Brutus Buckeye & The "Expert of One" Mindset2:15 - Why Leave Nursing? Burnout, Family, and Income8:45 - The Strategy: Networking with Peers vs. Hiring Managers15:30 - Master Class: Using the STAR Method in Interviews (Live Example)24:10 - The "Courage" Story: Challenging a Surgeon in the ICU32:45 - Must See: Interviewing for Pfizer While His Wife was in Labor!40:20 - The "Re-Close": How to Tell Them You Got the Job45:50 - Money Talk: Negotiating Base Salary, Commission, & Relocation ($158k Total)52:10 - Final Advice: Betting on YourselfWANT TO BREAK INTO MEDICAL SALES? Ready to leave the bedside or the classroom and start a 6-figure career? Apply to Medical Sales U today: medicalsalesu.com/ABOUT THE GUEST: Corey Stewart is a former Ohio State "Brutus" mascot, a Cardiovascular ICU Nurse, and now a Pharmaceutical Sales Representative at Pfizer. He successfully transitioned into the industry in just 11 weeks using the Medical Sales U coaching program.#MedicalSales #Pfizer #NurseToSales #SalaryNegotiation #OhioState #BrutusBuckeye #PharmaSales #CareerTransition #InterviewTips #DaveSterrett #MedicalSalesUDisclaimer: The views expressed in this video are those of the speakers and do not necessarily reflect the official policy or position of any other agency, organization, employer, or company.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jim Gale, Founding Partner & Managing Director at Signet.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jim, covering: The origins of growth equity in private equity and how it led to the founding of Signet, a fund built on deep domain expertise. Why private equity is a growing asset category but still remains undervalued and under appreciated. How the nature of the companies Signet invests in has evolved over the last twenty five years, while the fundamental principles of building a strong business remain the same. How the “picks and shovels” strategy of investing in tools, services and infrastructure has consistently served them well. Jim's assessment criteria when evaluating new opportunities after seventy deals, including the key question… can we institutionalise an entrepreneur led business. How higher interest rates and economic uncertainty constrain biopharma and biotech, and how that impacts investment dollars flowing into pharma services, along with deal flow, valuation and structure. James “Jim” Gale is the Founding Partner and Managing Director of Signet Healthcare Partners, a New York based healthcare growth equity firm specialising in pharmaceutical services, specialty pharma and medical technology. With more than thirty five years of investing and finance experience, Jim has built a deep track record backing companies involved in formulation, development, manufacturing and commercialisation across the world.   At Signet, Jim has led investments across the pharma services value chain, including platforms in sterile fill finish, complex formulations, biologics development and specialty generics. His current and recent board roles include Ascendia Pharmaceutical Solutions, NorthX Biologics, RK Pharma, Bionpharma, Chr Olesen Synthesis, Pharma Nobis, Juno Pharmaceuticals and Lee's Pharmaceutical. He also serves as Chairman of Bionpharma and is a director of Knight Therapeutics.   Jim holds an MBA from the University of Chicago Booth School of Business.   Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Dr. DebWhat if I told you that the stomach acid medication you’re taking for heartburn is actually causing the problem it’s supposed to solve that your doctor learned virtually nothing about nutrition, despite spending 8 years in medical school. That the very system claiming to heal you was deliberately designed over a hundred years ago by an oil tycoon, John D. Rockefeller, to create lifelong customers, not healthy people. Last week a patient spent thousands of dollars on tests and treatments for acid reflux, only to discover she needed more stomach acid, not less. The medication keeping her sick was designed to do exactly that. Today we’re exposing the greatest medical deception in modern history, how a petroleum empire systematically destroyed natural healing wisdom turned medicine into a profit machine. And why the treatments, keeping millions sick were engineered that way from the beginning. This isn’t about conspiracy theories. This is a documented history that explains why you feel so lost about your own body’s needs welcome back to let’s talk wellness. Now the show where we uncover the root causes of chronic illness, explore cutting edge regenerative medicine, and empower you with the tools to heal. I’m Dr. Deb. And today we’re diving into how the Rockefeller Medical Empire systematically destroyed natural healing wisdom and replaced it with profit driven systems that keeps you dependent on treatments instead of achieving true health. If you or someone you love has been running to the doctor for every minor ailment, taking acid blockers that seem to make digestive problems worse, or feeling confused about basic body functions that our ancestors understood instinctively. This episode is for you. So, as usual, grab a cup of coffee, tea, or whatever helps you unwind. Settle in and let’s get started on your journey to reclaiming your health sovereignty all right. So here we are talking about the Rockefeller Medical Revolution. Now, what if your symptoms aren’t true diagnosis, but rather the predictable result of a medical system designed over a hundred years ago to create lifelong customers instead of healthy people. Now I learned this when I was in naturopathic school over 20 years ago. And it hasn’t been talked about a lot until recently. Recently. People are exposing the truth about what actually happened in our medical system. And today I want to take you back to the early 19 hundreds to understand how we lost the basic health wisdom that sustained humanity for thousands of years. Yes, I said that thousands of years. This isn’t conspiracy theory. This is documented history. That explains why you feel so lost when it comes to your own body’s needs. You know by the turn of the 20th century. According to meridian health Clinic’s documentation. Rockefeller controlled 90% of all petroleum refineries in America and through ownership of the Standard Oil Corporation. But Rockefeller saw an opportunity that went far beyond oil. He recognized that petrochemicals could be the foundation for a completely new medical system. And here’s what most people don’t know. Natural and herbal medicines were very popular in America during the early 19 hundreds. According to Staywell, Copper’s historical analysis, almost one half of medical colleges and doctors in America were practicing holistic medicine, using extensive knowledge from Europe and native American traditions. People understood that food was medicine, that the body had natural healing mechanisms, and that supporting these mechanisms was the key to health. But there was a problem with the Rockefeller’s business plan. Natural medicines couldn’t be patented. They couldn’t make a lot of money off of them, because they couldn’t hold a patent. Petrochemicals, however, could be patented, could be owned, and could be sold for high profits. So Rockefeller and Andrew Carnegie devised a systematic plan to eliminate natural medicine and replace it with petrochemical based pharmaceuticals and according to E. Richard Brown’s comprehensive academic documentation in Rockefeller, medicine men. Medicine, and capitalism in America. They employed the services of Abraham Flexner, who proceeded to visit and assess every single medical school in us and in Canada. Within a very short time of this development, medical schools all around the us began to collapse or consolidate. The numbers are staggering. By 1910 30 schools had merged, and 21 had closed their doors of the 166 medical colleges operating in 19 0, 4, a hundred 33 had survived by 1910 and a hundred 4 by 1915, 15 years later, only 76 schools of medicine existed in the Us. And they all followed the same curriculum. This wasn’t just about changing medical education. According to Staywell’s copper historical analysis. Rockefeller and Carnegie influenced insurance companies to stop covering holistic treatments. Medical professionals were trained in the new pharmaceutical model and natural solutions became outdated or forgotten. Not only that alternative healthcare practitioners who wanted to stay practicing in alternative medicine were imprisoned for doing so as documented by the potency number 710. The goal was clear, create a system where scientists would study how plants cure disease, identify which chemicals in the plants were effective and then recreate a similar but not identical chemical in the laboratory that would be patented. E. Richard Brown’s documents. The story of how a powerful professional elite gained virtual homogeny in the western theater of healing by effectively taking control of the ethos and practice of Western medicine. The result, according to the healthcare spending data, the United States now spends 17.6% of its Gdp on health care 4.9 trillion dollars in 2023, or 14,570 per person nearly twice as much as the average Oecd country. But it doesn’t focus on cure. But on symptoms, and thus creating recurring clients. This systematic destruction of natural medicine explains why today’s healthcare providers often seem baffled by simple questions about nutrition why they immediately reach for a prescription medication for minor ailments, and why so many people feel disconnected from their own body’s wisdom. We’ve been trained over 4 generations to believe that our bodies are broken, and that symptoms are diseases rather than messages, and that external interventions are always superior to supporting natural healing processes. But here’s what they couldn’t eliminate your body’s innate wisdom. Your digestive system still functions the same way it did a hundred years ago. Your immune system still follows the same patterns. The principles of nutrition, movement and stress management haven’t changed. We’ve just forgotten how to listen and respond. We’re gonna take a small break here and hear from our sponsor. When we come back. We’re gonna talk about the acid reflux deception, and why your cure is making you sicker, so don’t go away all right, welcome back. So I want to give you a perfect example of how Rockefeller medicine has turned natural body wisdom upside down, the treatment of acid, reflux, and heartburn. Every single day in my practice I see patients who’ve been taking acid blocker medications, proton pump inhibitors like prilosec nexium or prevacid for years, not for weeks, years, and sometimes even decades. They come to me because their digestive problems are getting worse, not better. They have bloating and gas and nutrition deficiencies. And we’re seeing many more increased food sensitivities. And here’s what’s happening in the Us. Most people often attribute their digestive problems to too much stomach acid. And they use medications to suppress the stomach acid, but, in fact symptoms of chronic acid, reflux, heartburn, or gerd, can also be caused by too little stomach acid, a condition called hyper. Sorry hypochlorhydria normal stomach acid has a Ph level of one to 2, which is highly acidic. Hydrochloric acid plays an important role in your digestion and your immunity. It helps to break down proteins and absorb essential nutrients, and it helps control viruses and bacteria that might otherwise infect your stomach. But here’s the crucial part that most people don’t understand, and, according to Cleveland clinic, your stomach secretes lower amounts of hydrochloric acid. As you age. Hypochlorhydria is more common in people over the age of 40, and even more common over the age of 65. Webmd states that the stomach acid can produce less acid as a result of aging and being 65 or older is a risk factor for developing hypochlorhydria. We’ve been treating this in my practice for a long time. It’s 1 of the main foundations that we learn as naturopathic practitioners and as naturopathic doctors, and there are times where people need these medications, but they were designed to be used short term not long term in a 2,013 review published in Medical News today, they found that hypochlorhydria is the main change in the stomach acid of older adults. and when you have hypochlorydria, poor digestion from the lack of stomach, acid can create gas bubbles that rise into your esophagus or throat, carrying stomach acid with them. You experience heartburn and assume that you have too much acid. So you take acid blockers which makes the underlying problem worse. Now, here’s something that will shock you. PPI’s protein pump inhibitors were originally studied and approved by the FDA for short-term use only according to research published in us pharmacists, most cases of peptic ulcers resolve in 6 to 8 weeks with PPI therapy, which is what these medications were created for. Originally the American family physician reports that for erosive esophagitis. Omeprazole is indicated for short term 4 to 8 weeks. That’s it. Treatment and healing and done if needed. An additional 4 to 8 weeks of therapy may be considered and the University of Minnesota College of Pharmacy, States. Guidelines recommended a treatment duration of 8 weeks with standard once a day dosing for a PPI for Gerd. The Canadian family physician, published guidelines where a team of healthcare professionals recommended prescribing Ppis in adults who suffer from heartburn and who have completed a minimum treatment of 4 weeks in which symptoms were relieved. Yet people are taking these medications for years, even decades far beyond their intended duration of use and a study published in Pmc. Found that the threshold for defining long-term PPI use varied from 2 weeks to 7 years of PPI use. But the most common definition was greater than one year or 6 months, according to the research in clinical context, use of Ppis for more than 8 weeks could be reasonably defined as long-term use. Now let’s talk about what these acid blocker medications are actually doing to your body when used. Long term. The research on long term PPI use is absolutely alarming. According to the comprehensive review published in pubmed central Pmc. Long-term use of ppis have been associated with serious adverse effects, including kidney disease, cardiovascular disease fractures because you’re not absorbing your nutrients, and you’re being depleted. Infections, including C. Diff pneumonia, micronutrient deficiencies and hypomagnesium a low level of magnesium anemia, vitamin, b, deficiency, hypocalcemia, low calcium, low potassium. and even cancers, including gastric cancer, pancreatic cancer, colorectal cancer. And hepatic cancer and we are seeing all of these cancers on a rise, and we are now linking them back to some of these medications. Mayo clinic proceedings published research showing that recent studies regarding long-term use of PPI medication have noted potential adverse effects, including risks of fracture, pneumonia, C diff, which is a diarrhea. It’s a bacteria, low magnesium, low b 12 chronic kidney disease and even dementia. And a 2024 study published in nature communications, analyzing over 2 million participants from 5 cohorts found that PPI use correlated with increased risk of 15 leading global diseases, such as ischemic heart disease. Diabetes, respiratory infections, chronic kidney disease. And these associations showed dose response relationships and consistency across different PPI types. Now think about this. You take a medication for heartburn that was designed for 4 to 8 weeks of use, and when used long term, it actually increases your risk of life, threatening infections, kidney disease, and dementia. This is the predictable result of suppressing a natural body function that exists for important reasons. Hci plays a key role in many physiological processes. It triggers, intestinal hormones, prepares folate and B 12 for absorption, and it’s essential for absorption of minerals, including calcium, magnesium, potassium, zinc, and iron. And when you block acid production, you create a cascade of nutritional deficiencies and immune system problems that often manifest as seemingly unrelated health issues. So what’s the natural approach? Instead of suppressing stomach acid, we need to support healthy acid production and address the root cause of reflux healthcare. Providers may prescribe hcl supplements like betaine, hydrochloric acid. Bhcl is what it’s called. Sometimes it’s called betaine it’s often combined with enzymes like pepsin or amylase or lipase, and it’s used to treat hydrochloric acid deficiency, hypochlorhydria. These supplements can help your digestion and sometimes help your stomach acid gradually return back to normal levels where you may not need to use them all the time. Simple strategies include consuming protein at the beginning of the meal to stimulate Hcl production, consume fluids separately at least 30 min away from meals, if you can, and address the underlying cause like chronic stress and H. Pylori infections. This is such a sore subject for me. So many people walk around with an H. Pylori infection. It’s a bacterial infection in the stomach that can cause stomach ulcers, causes a lot of stomach pain and burning. and nobody is treating the infection. It’s a bacterial infection. We don’t treat this anymore with antibiotics or antimicrobials. We treat it with Ppis. But, Ppis don’t fix the problem. You have to get rid of the bacteria once the bacteria is gone, the gut lining can heal. Now it is a common bacteria. It can reoccur quite frequently. It’s highly contagious, so you can pick it up from other people, and it may need multiple courses of treatment over a person’s lifetime. But you’re actually treating the problem. You’re getting rid of the bacteria that’s creating the issue instead of suppressing the acid. That’s not fixing the bacteria which then leads to a whole host of other problems that we just talked about. There are natural approaches to increase stomach acid, including addressing zinc deficiency. And since the stomach uses zinc to produce Hcl. Taking probiotics to help support healthy gut bacteria and using digestive bitters before meals can be really helpful. This is exactly what I mean about reclaiming the body’s wisdom. Instead of suppressing natural functions, we support them instead of creating drug dependency, we restore normal physiology. Instead of treating symptoms indefinitely, we address the root cause and help the body heal itself. In many cultures. Bitters is a common thing to use before or after a meal. But yet in the American culture we don’t do that anymore. We’ve not passed on that tradition. So very few people understand how to use bitters, or what bitters are, or why they’re important. And these basic things that can be used in your food and cooking and taking could replace thousands of dollars of medication that you don’t really need. That can create many more problems along the way. Now, why does your doctor know nothing about nutrition. Well, I want to address something that might shock you all. The reason your doctor seems baffled when you ask about nutrition isn’t because they’re not intelligent. It’s because they literally never learned this in medical school statistics on nutritional education in medical schools are staggering and help explain why we have such a health literacy crisis in America. According to recent research published in multiple academic journals, only 27% of Us. Medical schools actually offer students. The recommended 25 h of nutritional training across 4 years of medical school. That means 73% of the medical schools don’t even meet the minimum standards set in 1985. But wait, it gets worse. A 2021 survey of medical schools in the Us. And the Uk. Found that most students receive an average of only 11 h of nutritional training throughout their entire medical program. and another recent study showed that in 2023 a survey of more than a thousand Us. Medical students. About 58% of these respondents said they received no formal nutritional education while in medical school. For 4 years those who did averaged only 3 h. I’m going to say this again because it’s it’s huge 3 h of nutritional education per year. So let me put this in perspective during 4 years of medical school most students spend fewer than 20 h on nutrition that’s completely disproportionate to its health benefits for patients to compare. They’ll spend hundreds of hours learning about pharmaceutical interventions, but virtually no time learning how food affects health and disease. Now, could this be? Why, when we talk about nutrition to lower cholesterol levels or control your diabetes, they blow you off, and they don’t answer you. It’s because they don’t understand. But yet what they’ll say is, people won’t change their diet. That’s why you have to take medication. That’s not true. I will tell you. I work with people every single day who are willing to change their diet. They’re just confused by all the information that’s out there today about nutrition. And what diet is the right diet to follow? Do I do, Paleo? Do I do? Aip? Do I do carnivore? Do I do, Keto? Do I do? Low carb? There’s so many diets out there today? It’s confusing people. So I digress. But let’s go back. So here’s the kicker. The limited time medical students do spend on nutrition office often focuses on nutrients think proteins and carbohydrates rather than training in topics such as motivational interviewing or meal planning, and as one Stanford researcher noted, we physicians often sound like chemists rather than counselors who can speak with patients about diet. Isn’t that true? We can speak super high level up here, but we can’t talk basics about nutrition. And this explains why only 14% of the physicians believe they were adequately trained in nutritional counseling. Once they entered practice and without foundational concepts of nutrition in undergrad work. Graduate medical education unsurprisingly falls short of meeting patients, needs for nutritional guidance in clinical practice, and meanwhile diet, sensitive chronic diseases continue to escalate. Although they are largely preventable and treatable by nutritional therapies and dietary. Lifestyle changes. Now think about this. Diet. Related diseases are the number one cause of death in the Us. The number one cause. Yet many doctors receive little to no nutritional education in medical school, and according to current health statistics from 2017 to march of 2020. Obesity prevalence was 19.7% among us children and adolescents affecting approximately 14.7 million young people. About 352,000 Americans, under the age of 20, have been diagnosed with diabetes. Let me say this again, because these numbers are astounding to me. 352,000 Americans, under the age of 20, have been diagnosed with diabetes with 5,300 youth diagnosed with type, 2 diabetes annually. Yet the very professionals we turn to for health. Guidance were never taught how food affects these conditions and what drug has come to the rescue Glp. One S. Ozempic wegovy. They’re great for weight loss. They’re great for treating diabetes. But why are they here? Well, these numbers are. Why, they’re here. This is staggering to put 352,000 Americans under the age of 20 on a glp, one that they’re going to be on for the rest of their lives at a minimum of $1,200 per month. All we have to do is do the math, you guys, and we can see exactly what’s happening to our country, and who is getting rich, and who is getting the short end of the stick. You’ve become a moneymaker to the pharmaceutical industry because nobody has taught you how to eat properly, how to live, how to have a healthy lifestyle, and how to prevent disease, or how to actually reverse type 2 diabetes, because it’s reversible in many cases, especially young people. And we do none of that. All we do is prescribe medications. Metformin. Glp, one for the rest of your life from 20 years old to 75, or 80, you’re going to be taking medications that are making the pharmaceutical companies more wealth and creating a disease on top of a disease on top of a disease. These deficiencies in nutritional education happen at all levels of medical training, and there’s been little improvement, despite decades of calls for reform. In 1985, the National Academy of Sciences report that they recommended at least 25 h of nutritional education in medical school. But a 2015 study showed only 29% of medical schools met this goal, and a 2023 study suggests the problem has become even worse. Only 7.8% of medical students reported 20 or more hours of nutritional education across all 4 years of medical school. This systemic lack of nutrition, nutritional education has been attributed to several factors a dearth of qualified instructors for nutritional courses, since most physicians do not understand nutrition well enough to teach it competition for curriculum time, with schools focusing on pharmaceutical interventions rather than lifestyle medicine and a lack of external incentives that support schools, teaching nutrition. And ironically, many medical schools are part of universities that have nutrition departments with Phd. Trained professors who could fill this gap by teaching nutrition in medical schools but those classes are often taught by physicians who may not have adequate nutritional training themselves. This explains so much about what I see in my practice. Patients come to me confused and frustrated because their primary care doctors can’t answer basic questions about how food affects their health conditions. And these doctors aren’t incompetent. They simply were never taught this information. And the result is that these physicians graduate, knowing how to prescribe medications for diabetes, but not how dietary changes can prevent or reverse it. They can treat high blood pressure with pharmaceuticals, but they may not know that specific nutritional approaches can be equally or more effective. This isn’t the doctor’s fault. It’s the predictable result of medical education systems that was deliberately designed to focus on patentable treatments rather than natural healing approaches. And remember this traces back to the Rockefeller influence on medical education. You can’t patent an apple or a vegetable. But you can patent a drug now. Why can’t we trust most medical studies? Well this just gets even better. I need to address something that’s crucial for you to understand as you navigate health information. Why so much of the medical research you hear about in the news is biased, and why peer Review isn’t the gold standard of truth you’ve been told it is. The corruption in medical research by pharmaceutical companies is not a conspiracy theory. It’s well documented scientific fact, according to research, published in frontiers, in research, metrics and analytics. When pharmaceutical and other companies sponsor research, there is a bias. A systematic tendency towards results serving their interests. But the bias is not seen in the formal factors routinely associated with low quality science. A Cochrane Review analyzed 75 studies of the association between industry, funding, and trial results, and these authors concluded that trials funded by a drug or device company were more likely to have positive conclusions and statistically significant results, and that this association could not be explained by differences in risk of bias between industry and non-industry funded trials. So think about that. According to the Cochrane collaboration, industry funding itself should be considered a standard risk of bias, a factor in clinical trials. Studies published in science and engineering ethics show that industry supported research is much more likely to yield positive outcomes than research with any other sponsorship. And here’s how the bias gets introduced through choice of compartor agents, multiple publications of positive trials and non-publication of negative trials reinterpreting data submitted to regulatory agencies, discordance between results and conclusions, conflict of interest leading to more positive conclusions, ghostwriting and the use of seating trials. Research, published in the American Journal of Medicine. Found that a result favorable to drug study was reported by all industry, supported studies compared with two-thirds of studies, not industry, supported all industry, supported studies showed favorable results. That’s not science that’s marketing, masquerading as research. And according to research, published in sciencedirect the peer review system which we’re told ensures quality. Science has a major limitation. It has proved to be unable to deal with conflicts of interest, especially in big science contexts where prestigious scientists may have similar biases and conflicts of interest are widely shared among peer reviewers. Even government funded research can have conflicts of interest. Research published in pubmed States that there are significant benefits to authors and investigators in participating in government funded research and to journals in publishing it, which creates potentially biased information that are rarely acknowledged. And, according to research, published in frontiers in research, metrics, and analytics, the pharmaceutical industry has essentially co-opted medical knowledge systems for their particular interests. Using its very substantial resources. Pharmaceutical companies take their own research and smoothly integrate it into medical science. Taking advantage of the legitimacy of medical institutions. And this corruption means that much of what passes for medical science is actually influenced by commercial interests rather than pursuant of truth. Research published in Pmc. Shows that industry funding affects the results of clinical trials in predictable directions, serving the interests of the funders rather than the patients. So where can we get this reliable, unbiased Health information, because this is critically important, because your health decisions should be based on the best available evidence, not marketing disguised as science. And so here are some sources that I recommend for trustworthy health and nutritional information. They’re independent academic sources. According to Harvard Chan School of public health their nutritional, sourced, implicitly states their content is free from industry, influence, or support. The Linus Pauling Institute, Micronutrient Information Center at Oregon State University, which, according to the Glendale Community college Research Guide provides scientifically accurate information about vitamins, minerals, and other dietary factors. This Institute has been around for decades. I’ve used it a lot. I’ve gotten a lot of great information from them. Very, very trustworthy. According to the Glendale Community College of Nutrition Resource guide Tufts, University of Human Nutritional Research Center on aging is one of 6 human nutrition research centers supported by the United States Department of Agriculture, the Usda. Their peer reviewed journals with strong editorial independence though you must still check funding resources. And how do you evaluate this information? Online? Well, according to medlineplus and various health literacy guides when evaluating health information medical schools and large professional or nonprofit organizations are generally reliable sources, but remember, it is tainted by the Rockefeller method. So, for example, the American College of cardiology. Excuse me. Professional organization and the American Heart Institute a nonprofit are both reliable sources. Sorry about that of information on heart health and watch out for ads designed to look like neutral health information. If the site is funded by ads they should be clearly marked as advertisements. Excuse me, I guess I’m talking just a little too much now. So when the fear of medicine becomes deadly. Now, I want to address something critically important that often gets lost in conversations about health, sovereignty, and questioning the medical establishment. And while I’ve spent most of this episode explaining how the Rockefeller medical system has created dependency and suppressed natural healing wisdom. There’s a dangerous pendulum swing happening that I see in my practice. People becoming so fearful of pharmaceutical interventions that they refuse lifesaving treatments when they’re genuinely needed. This is where balance and clinical judgment become absolutely essential. Yes, we need to reclaim our basic health literacy and reduce our dependency on unnecessary medical interventions. But there are serious bacterial infections that require immediate antibiotic treatment, and the consequences of avoiding treatment can be devastating or even fatal. So let me share some examples from research that illustrate when antibiotic fear becomes dangerous. Let’s talk about Lyme disease, and when natural approaches might not be enough. The International Lyme Disease Association ilads has conducted extensive research on chronic lyme disease, and their findings are sobering. Ileds defines chronic lyme disease as a multi-system illness that results from an active and ongoing infection of pathogenic members of the Borrelia Brdorferi complex. And, according to ilads research published in their treatment guidelines, the consequences of untreated persistent lyme infection far outweigh the potential consequences of long-term antibiotic therapy in well-designed trials of antibiotic retreatment in patients with severe fatigue, 64% in the treatment arm obtained clinically significant and sustained benefit from additional antibiotic therapy. Ilas emphasizes that cases of chronic borrelia require individualized treatment plans, and when necessary antibiotic therapy should be extended their research demonstrates that 20 days of prophylactic antibiotic treatment may be highly effective for preventing the onset of lyme disease. After known tick bites and patients with early Lyme disease may be best served by receiving 4 to 6 weeks of antibiotic therapy. Research published in Pmc. Shows that patients with untreated infections may go on to develop chronic, debilitating, multisystem illnesses that is difficult to manage, and numerous studies have documented persistent Borrelia, burgdorferi infection in patients with persistent symptoms of neurological lyme disease following short course. Antibiotic treatment and animal models have demonstrated that short course. Antibiotic therapy may fail to eradicate lyme spirochetes short course is a 1 day. One pill treatment of doxycycline. Or less than 20 days of antibiotics, is considered a short course. It’s not long enough to kill the bacteria. The bacteria’s life cycle is about 21 days, so if you don’t treat the infection long enough, the likelihood of that infection returning is significant. They’ve also done studies in the petri dish, where they show doxycycline being put into a petri dish with active lyme and doxycycline does not kill the infection, it just slows the replication of it. Therefore, using only doxycycline, which is common practice in lyme disease may not completely eradicate that infection for you. So let’s talk about another life threatening emergency. C. Diff clostridia difficile infection, which represents another example where antibiotic treatment is absolutely essential, despite the fact that C diff itself is often triggered by antibiotic use. According to Cleveland clinic C. Diff is estimated to cause almost half a million infections in the United States each year, with 500,000 infections, causing 15,000 deaths each year. Studies reported by Pmc. Found thirty-day Cdi. Mortality rates ranging from 6 to 11% and hospitalized Cdi patients have significantly increased the risk of mortality and complications. Research published in Pmc shows that 16.5% of Cdi patients experience sepsis and that this increases with reoccurrences 27.3% of patients with their 1st reoccurrence experience sepsis. While 33.1% with 2 reoccurrences and 43.2% with 3 or more reoccurrences. Mortality associated with sepsis is very high within hospital 30 days and 12 month mortality rates of 24%, 30% and 58% respectively. According to the Cdc treatment for C diff infection usually involves taking a specific antibiotic, such as vancomycin for at least 10 days, and while this seems counterintuitive, treating an antibiotic associated infection with more antibiotics. It’s often lifesaving. Now let’s talk about preventing devastating complications. Strep throat infections. Provide perhaps the clearest example of when antibiotic treatment prevents serious long-term consequences, and, according to Mayo clinic, if untreated strep throat can cause complications such as kidney inflammation and rheumatic fever. Rheumatic fever can lead to painful and inflamed joints, and a specific type of rash of heart valve damage. We also know that strep can cause pans pandas, which is a systemic infection, often causing problems with severe Ocd. And anxiety and affecting mostly young people. The research is unambiguous. According to the Cleveland clinic. Rheumatic fever is a rare complication of untreated strep, throat, or scarlet fever that most commonly affects children and teens, and in severe cases it can lead to serious health problems that can affect your child’s heart. Joints and organs. And research also shows that the rate of development of rheumatic fever in individuals with untreated strep infections is estimated to be 3%. The incidence of reoccurrence with a subsequent untreated infection is substantially greater. About 50% the rate of development is far lower in individuals who have received antibiotic treatment. And according to the World health organization, rheumatic heart disease results from the inflammation and scarring of the heart valves caused by rheumatic fever, and if rheumatic fever is not treated promptly, rheumatic heart disease may occur, and rheumatic heart disease weakens the valves between the chambers of the heart, and severe rheumatic heart disease can require heart surgery and result in death. The who states that rheumatic heart disease remains the leading cause of maternal cardiac complications during pregnancy. And additionally, according to the National Kidney foundation. After your child has either had throat or skin strep infection, they can develop post strep glomerial nephritis. The Strep bacteria travels to the kidneys and makes the filtering units of the kidneys inflamed, causing the kidneys to be able to unable or less able to fill and filter urine. This can develop one to 2 weeks after an untreated throat infection, or 3 to 4 weeks after an untreated skin infection. We need to find balance. And here’s what I want you to understand. Questioning the medical establishment and developing health literacy doesn’t mean rejecting all medical interventions. It means developing the wisdom to know when they’re necessary and lifesaving versus when they’re unnecessary and potentially harmful. When I see patients with confirmed lyme disease, serious strep infections or life. Threatening conditions like C diff. I don’t hesitate to recommend appropriate therapy but I also work to support their overall health address, root causes, protect and restore their gut microbiome and help them recover their natural resilience. The goal isn’t to avoid all medical interventions. It’s to use them wisely when truly needed, while simultaneously supporting your body’s inherent healing capacity and addressing the lifestyle factors that created the vulnerability. In the 1st place. All of this can be extremely overwhelming, and it can be frightening to understand or learn. But remember, the power that you have is knowledge. The more you learn about what’s actually happening in your health, in understanding nutrition. in learning what your body wants to be fed, and how it feels, and working with practitioners who are holistic in nature, natural, integrative, functional, whatever we want to call that these days. The more you can learn from them, the more control you have over your own health and what I would urge you to do is to teach your children what you’re learning. Teach them how to live a healthy lifestyle, teach them how to keep a clean environment. This is how we take back our own health. So thank you for joining me today on, let’s talk wellness. Now, if this episode resonated with you. Please share it with someone who could benefit from understanding how the Rockefeller medical system has shaped our approach to health, and how to reclaim your body’s wisdom while using medical care appropriately when truly needed. Remember, wellness isn’t just about feeling good. It’s about understanding your body, trusting its wisdom, supporting its natural healing capacity, and knowing when to seek appropriate medical intervention. If you’re ready to explore how functional medicine can help you develop this deeper health knowledge while addressing root causes rather than just managing symptoms. You can get more information from serenityhealthcarecenter.com, or reach out directly to us through our social media channels until next time. I’m Dr. Dab, reminding you that your body is your wisest teacher. Learn to listen, trust the process, use medical care wisely when needed, and take care of your body, mind, and spirit. Be well, and we’ll see you on the next episode.The post Episode 250 -The Great Medical Deception first appeared on Let's Talk Wellness Now.

Episode 95 of Astonishing Healthcare features six previous guests on the show who share astonishing observations from 2025 and some bold predictions for the New Year! Industry veteran Jeffrey Hogan, our General Counsel and Chief Compliance Officer, Lloyd Fiorini, ERISA law expert Nick Welle, two of our clinical leaders – Sarra Izadi, PharmD, Chief Clinical Officer, and Bonnie Hui-Callahan, PharmD, CDCES, Sr. Director, Clinical Programs, and our Chief Technology Officer and Co-Founder, Ryan Kelly, joined us for this round-robin discussion that's packed with insightful reflections and optimism about the future. We won't ruin it in the show notes, but based on what we saw in 2025: Everyone has finally had enough of the costs and opacity of the U.S. healthcare system – a $70k family premium is truly astonishing It's surprising that, despite the lawsuits, warnings, and reform efforts, the proverbial hammer didn't drop on anyone for not being a good health plan fiduciary The speed and impact of AI have broadly been more positive than expected The rise of cardio-diabesity How GLP-1s helped shift the balance of power in the pharmaceutical supply chain And in 2026, we may see: Employers fight back – they take agency over their plans, and for first movers that started with transitioning to aligned PBMs, it's “game on” for the rest of their health plans The cash price – or acquisition cost – of drugs in the U.S. becomes the baseline – i.e., we finally see a real change in how drugs are priced ICHRAs and other alternative models become more popular Employers look to new clinical programs and models that demonstrate a return on their spending AI become more important for clinical workflows (not decision-making, at least not yet) Pharmaceutical manufacturers find themselves with increasing bargaining power vs. traditional PBMs A new Stanley Cup champion, and a Super Bowl ring for… Related Content Judi Health Policy Pulse: 2025 Regulatory Roundup, the Push for PBM Reform Replay - Unifying Medical and Pharmacy Benefits: The Blueprint for Better Employee Health and Wellness AH094 - How Unified Claims Processing Evolved from Pharmacy: Improving Member Care & Operating Efficiency Health Benefits 101: The Importance of Clinical Programs How to obtain Rx data and what to do with it For more information about Capital Rx and this episode, please visit Judi Health - Insights.

Listen in as our expert panel discusses evidence-based approaches to help patients quit smoking, vaping, and using other nicotine products. You'll gain practical insights on medication selection, combination strategies, and tailored approaches for helping patients break free from nicotine addiction.Special guest:Robin Corelli, PharmD, CTTS, FCSHPProfessor of Clinical PharmacySchool of PharmacyUniversity of California, San FranciscoYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLMClinical Associate Professor of Family MedicinePrisma Health/USC-SOMG Family Medicine Residency ProgramUSC School of Medicine GreenvilleCraig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in November 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources related to this podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: Chart: Smoking Cessation Drug TherapyFAQ: E-Cigarettes and VapingChart: Dos and Don'ts With PatchesArticle: Help Patients Send Their Vaping Habits Up in Smoke Use code mt1026 at checkout for 10% off a new or upgraded subscription.Send us a textEmail us: ContactUs@trchealthcare.com. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. Learn more about our product offerings at trchealthcare.com.

Start making $150k - $200k+ in your first year of medical sales. Stop chasing crowded "old school" roles like Orthopedics and Spine. The real money—and the life-saving innovation—is in Oncology and Specialty Pharma. Today, I reveal the exact blueprint to reinvent your career and break into the most lucrative sector of healthcare. Whether you're a nurse, a teacher, or stuck in a "middle-class mindset," this episode breaks down why your background doesn't matter. Only your preparation does.I share my personal journey from a non-profit minister making $70k to a high-level oncology rep, and explain why "casual advice" from friends will get you rejected. If you want to master the interview, crush your clinical knowledge, and build a 6-figure life, this is the masterclass you need.WHAT YOU WILL LEARN IN THIS EPISODE:- The "Gold Rush" Shift: Why you should ignore Orthopedics and focus entirely on Oncology, Diagnostics, and Genetic Testing.- The 3 Essential Mindset Shifts: How to move from "winging it" to becoming an obsessively prepared candidate.- Real Success Stories: How Kanika (immigrant to Dallas), Sydney (nurse), and others went from zero experience to $200k roles.- The "Ride-Along" Trap: Why you need a brutal coach, not a nice mentor.- The HEART Framework: The 5 character traits (Humility, Energy, Active Listening, Resilience, Trust) that hiring managers look for.- Confidence vs. Arrogance: How to show "grit" without sounding like a jerk.- Daily Habits of Top 1% Earners: The 5 AM club, the "20 LinkedIn adds" rule, and why your degree (MBA) has a lower ROI than coaching.- The Michael Jordan Rule: Why even the greatest of all time hired coaches for their specific weaknesses.TIMESTAMPS00:00 - Introduction: The Program Focus (Oncology vs. Orthopedics)01:34 - Dave's Story: Reinventing Career from Ministry to Medical Sales03:44 - Success Stories: How Nurses & Immigrants Got Hired (Kanika, Sydney)06:47 - Mindset Shift #1: Be Coachable (Why Friends Can't Help You)09:20 - Mastering Virtual Interviews (Lighting, Camera & Background)10:32 - Mindset Shift #2: Be Curious (Understanding Clinical Trials & FDA)12:32 - Salary Reality: Device Associate ($80k) vs. Oncology ($155k+)13:55 - Mindset Shift #3: Collaboration (Working with MSLs & Nurse Navigators)16:28 - Confidence vs. Arrogance (The "Grit" Trap)18:02 - The H.E.A.R.T. Framework (Humility, Energy, Listening, Resilience, Trust)19:00 - Daily Habits: 5 AM Wake-ups, LinkedIn Strategy & Handling Rejection20:00 - The"Middle Class Mindset" Trap: Why Degrees Have Low ROI22:25 - Using AI for Resumes Without Sounding Like a Robot25:55 - The "Why": Patient Outcomes & Life-Extending Impact29:35 - The 3 Questions You Must Ask Yourself31:01 - The Michael Jordan Analogy: Why Even the Best Hire Coaches.ABOUT MEDICAL SALES U: Medical Sales U is the premier training program for professionals looking to break into high-paying careers in Medical Device, Pharmaceutical, and Genetic Testing sales. We turn "outsiders" into top 1% candidates.CONNECT WITH US: Learn more about coaching and career support at medicalsalesu.com/#MedicalSales #OncologySales #CareerPivot #SalesCoaching #HighIncomeSkills #DaveSterrett #MedicalSalesYou #InterviewTips #SalesJobs #PharmaceuticalSales

How can pharma and healthcare organizations balance innovation, AI, and privacy compliance?In this episode of FIT4Privacy, Punit joined by Timothy Nobles, a leading expert in data privacy and healthcare innovation, to explore how organizations can responsibly use data while staying compliant with global regulations like GDPR and HIPAA.If you're passionate about the intersection of privacy, data, and healthcare innovation, this conversation is a must-listen.

In this solo episode, Dr. Mike discusses the common issue of nocturia, where individuals frequently wake up at night to urinate, which disrupts sleep. The episode covers the root causes including sleep apnea, enlarged prostate, and overactive bladder, and dives into the roles of antidiuretic hormone (ADH) and atrial natriuretic peptide (ANP). It provides a comprehensive guide on addressing nocturia through behavioral modifications such as fluid restriction and sleep hygiene, supplements like pumpkin seed extract and beta-sitosterol, and pharmaceuticals including Desmopressin and alpha-blockers. The host also touches on treating sleep apnea with CPAP machines and mandibular advancement devices, emphasizing the importance of targeting the root cause for effective treatment.   Links: CPAP (Continuous Positive Airway Pressure) Beta-Sitosterol Desmopressin (Synthetic ADH) Show Notes: 00:00 Understanding nocturia and its connection to sleep apnea 01:00 Introduction and episode overview 02:00 Defining nocturia and its impact on sleep 03:00 Types of nocturia and their causes 04:30 The role of hormones in nocturia 05:30 Sleep apnea and its effects on nocturia 15:30 Behavioral modifications to reduce nocturia 24:00 Supplements for managing nocturia 30:00 Pharmaceutical solutions for nocturia   — The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to  cutting through the noise and uncovering the most effective strategies for optimizing health,  longevity, and peak performance. This podcast dives deep into evidence-based approaches to  hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise  protocols, leveraging sunlight light, and de-prescribing pharmaceuticals—using medications only when absolutely necessary.   Beyond health science, we tackle the intersection of public health and politics, exposing how  policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being.   Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen).   If you're ready to take control of your health and performance, this is the podcast for you. We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being.   Connect on social with Dr. Mike Hart: Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart  

Fighter Pilot Survival: Kegan Gill's Battle Beyond the Battlefield In this extraordinary episode, Marcus and Melanie meet with retired U.S. Navy Fighter Pilot Kegan Gill, whose story is nothing short of miraculous. Kegan survived a catastrophic ejection from his aircraft during a training mission over the Atlantic Ocean, where he ejected directly into the sound barrier. The injuries he sustained in that moment were severe enough to kill most people – his limbs torn apart and a traumatic brain injury among them. But Kegan's ordeal was only beginning. Plunged into the icy waters of the Atlantic with his parachute still attached, his wetsuit torn, and his arms unable to move, Kegan was forced to endure a two-hour battle with hypothermia as rescue teams raced to find him. Miraculously, his hypothermic state prevented fatal blood loss. Following this harrowing experience, Kegan faced months of grueling recovery, eventually achieving a perfect Physical Fitness Test score and returning to flight duty. However, Kegan's journey didn't end with physical recovery. He began experiencing severe psychotic episodes due to his brain injury, leading to a stint in a VA Mental Health Facility. Pharmaceutical treatments only worsened his symptoms, and he endured dehumanizing treatment from caregivers who misunderstood his unique needs. Now, Kegan is finding renewed hope through alternative treatments for brain health. Through the Warrior Angels Foundation, he has discovered the power of nutraceutical and hormonal interventions, offering a glimmer of healing. Beyond his personal health battles, Kegan is a dedicated father and husband, working tirelessly to support his young family. Join us as Kegan opens up about his incredible journey of survival, resilience, and healing. His story is as inspiring as it is shocking – a testament to human strength and the will to overcome even the darkest of circumstances. Tune in to hear a story of grit, determination, and the relentless pursuit of healing against all odds.  In This Episode You Will Hear: • When I was about 10 years old, my family had a friend that had a Cessna, and he took me up on this lawnmower with wings, and we went buzzing around, and it felt like a freakin' rocket ship. I absolutely loved being above the earth, and I felt so free. (6:36) • In May of 2012, I graduated as a winged aviator, and I got those wings pinned on my chest. (23:40) • [Marcus] It's an absolute transition into a different human being the minute those wings touch your chest. (24:02) • [In flight school] you showed up there, and you had your wings, and you thought you made it. They made it very clear you have not made anything yet. (26:40) • It just so happened on this day there was a 16 foot, 3,500 pound Great White Shark named Mary Lee directly under my airspace, and my buddy pointed out,  “Hey man, Today would be a terrible day to eject,” and an hour after having that conversation, I found myself out on what turned into a pretty freaking wild experience. (36:23) • [Melanie] Q: Is it common to eject?”  [Keegan] A: It happens more than you hear about in the news. We lose a few naval fighter jets every year to mishaps. (37:16) • When you show up at flight school, they say “Look to your left and look to your right. One of you is gonna have a serious mishap or be dead choosing this job. Are you sure you wanna be here?” (37:49) • You think you're invincible, and you don't really think anything of it. (38:04) • Keegan tells the detailed story of that fateful day. (Starting at 41:21) • When I punched out, I got the initial blast from the ejection seat, and then immediately impacted the sound barrier with my body. At that speed, the human body is not aerodynamic. (50:58) • The aircraft impacted the water so fast, it just vaporized. (52:50) • They ended up wheeling me in, and treated me for severe hyperthermia. They took my core body temperature. I was at 87 degrees. [Marcus] “That should've killed you.” (60:13) • One of the more senior guys takes me into his office and he goes: “Congratulations, Lieutenant Gill. If you can figure out how to get your body working again, we'll get you back in a Super Hornet. (68:14) • My brain was just not working the way it was supposed to from TBI (Traumatic Brain Injury). (75:04) • I had a deep sense of betrayal from all that thought I had served. To see the treatment, it seemed like everything I was fighting for was a joke. (89:53) • I've had a number of psychedelic-assisted therapies that have been really helpful. (95:54) • Ibogaine has been studied pretty thoroughly at this point. It's showing that it triggers neuro-regeneration. (102:21) Support Kegan: -  IG: kegansmurfgill - https://kegangill.com/?fbclid=PAZXh0bgNhZW0CMTEAAabtNw03Fww-lVt1LHf5b2iWrga-lLxSr_uJYqbNYUMN_NKoEMDqtfBd-Cw_aem_v5m2wI-nx5AKPUoeOA77pA Order His Book Here --> https://ballastbooks.com/purchase/phoenix-revival/ - IG: team_neverquit , marcusluttrell , melanieluttrell , huntero13 -  https://www.patreon.com/teamneverquit Support TNQ   - IG: team_neverquit , marcusluttrell , melanieluttrell , huntero13   -  https://www.patreon.com/teamneverquit Sponsors:   - Tractorsupply.com/hometownheroes   - Navyfederal.org        - mizzenandmain.com   [Promo code: TNQ20]    - masterclass.com/TNQ - Dripdrop.com/TNQ   - ShopMando.com [Promo code: TNQ]   - meetfabiric.com/TNQ   - Prizepicks (TNQ)   -  cargurus.com/TNQ    - armslist.com/TNQ    -  PXGapparel.com/TNQ   - bruntworkwear.com/TNQ    - shipsticks.com/TNQ    - stopboxusa.com {TNQ}    - ghostbed.com/TNQ [TNQ]   -  kalshi.com/TNQ   -  joinbilt.com/TNQ    - Tonal.com [TNQ]   - greenlight.com/TNQ   - drinkAG1.com/TNQ   - Hims.com/TNQ   - Shopify.com/TNQ

Are you a nurse or healthcare professional feeling burned out, underpaid, and stuck in a cycle of bureaucracy?Today, I reveal the 3-3-3 Framework: a blueprint specifically designed for bedside nurses who want to break into the high-paying world of Pharmaceutical and Medical Device Sales.If you are tired of missing holidays and hitting a salary ceiling, this episode explains exactly what you actually need to do to land offers like our student Sydney, who went from $68k to a $138k package.IN THIS EPISODE, YOU WILL LEARN:The 3 Reasons to Leave: Why burnout and lack of creativity are signs it's time to pivot.The 3 Barriers: Why relying on your degree and "following orders" kills your chances in sales interviews.The 3 Solutions: How to leverage your clinical edge and tap into the 10,000+ open roles in biotech right now.READY TO LAND YOUR DREAM JOB? Apply to Medical Sales University and learn how we help nurses double their income in 12 weeks: medicalsalesu.com/TIMESTAMPS00:00 - Intro: The shift from Bedside to Sales01:38 - The 3 Reasons healthcare workers are leaving (Burnout & Bureaucracy)03:13 - Why your career growth has stalled04:10 - The 3 Barriers: Why you aren't getting hired yet05:00 - The "Middle Class Mindset" trap (Degree vs. Skills)06:12 - Mindset Shift: From Compliance to Ownership09:18 - The 3 Solutions: How to finally break in10:52 - Success Story: How Sydney landed a $138k Oncology role12:50 - Why mentorship beats doing it aloneABOUT THE HOST: Dave Sterrett is the founder of Medical Sales University, the #1 program helping nurses, PTs, and healthcare professionals break into pharmaceutical and oncology sales.ABOUT MEDICAL SALES U: Medical Sales U is the premier training program for professionals looking to break into high-paying careers in Medical Device, Pharmaceutical, and Genetic Testing sales. We turn "outsiders" into top 1% candidates.CONNECT WITH US:Learn more about coaching and career support at medicalsalesu.com/#MedicalSales #NursingCareer #PharmaSales #NurseBurnout #CareerChange #MedicalDeviceSales #HighPayingJobs #Nurselife

Are you trying to break into medical sales but stuck deciding between Pharmaceutical and Medical Device? Or maybe you're curious about the high-growth world of Diagnostics and Genomics?Today, we discuss the differences in pay, lifestyle, and entry-level requirements for each path. Whether you want the adrenaline of the Operating Room or the stability of a $130k+ base salary in Pharma, this episode covers the 12 key distinctions you need to know before applying. IN THIS EPISODE YOU WILL LEARN:The Personality Test: Why "Engineers" love Device and "Scientists" love Pharma.The Paycheck: Real breakdown of base salaries vs. uncapped commissions.The Hidden Third Option: Why Oncology Diagnostics/Genomics might be the "Goldilocks" career path.Work-Life Balance: The reality of on-call surgical hours vs. the 9-to-5 pharma life.Success Stories: How a nurse (Sydney) and an immigrant (Kanika) broke in with $150k-$200k packages.READY TO BREAK IN? If you are struggling to get offers or don't know where to start, we help people from all backgrounds (nurses, coaches, teachers) launch their medical sales careers.Apply to Medical Sales U at medicalsalesu.com/TIMESTAMPS:00:00 - Intro: The common dilemma (O.R. vs. Samples).01:06 - The 3 Paths: Pharma, Device, and Diagnostics.02:15 - Science vs. Engineering: Which fits your brain?04:35 - Salary Reveal: Entry-level Pharma Pay ($95k-$135k base).06:10 - The "Associate" Role: Why Device base pay starts lower.07:40 - The Top 1%: Earning potential ($300k - $750k).09:15 - Diagnostics Pay: The sweet spot?10:30 - The Sales Process: Who are you actually selling to?13:50 - Lifestyle Check: Early mornings vs. Family flexibility.17:15 - Career Advancement: From Rep to Regional Director.22:15 - Student Success: From $68k to $200k total comp.ABOUT MEDICAL SALES U: Medical Sales U is the premier training program for professionals looking to break into high-paying careers in Medical Device, Pharmaceutical, and Genetic Testing sales. We turn "outsiders" into top 1% candidates.CONNECT WITH US:Learn more about coaching and career support at medicalsalesu.com/#MedicalSales #PharmaceuticalSales #MedDevice #SalesCareer #DaveSterritt #CareerAdvice #HighPayingJobs #SalesTips

Not gonna give much of an introduction here because this is a short bonus level set, but I did just wanna call everyone's attention to the "arms race" created by our status quo purchasing and selling of many things, pharmaceuticals included. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. For example, raise the list price of a drug to maximize rebates, because the higher the list, the bigger the discount you can give, which then exacerbates patient affordability because coinsurance is often based on list price. But then Pharma starts offering co-pay cards, which messes up the whole PBM (pharmacy benefit manager) plan to drive patients to their highest-rebate products (ie, the most profitable products). So then maximizers and accumulators enter the chat, and prior auths ramp up because plans start having to raise premiums after enough 340B drugs with high lists and no rebates, and then there's no cost containment and raise deductibles and around and around we go. Meanwhile, is this drug fundamentally worth the list price or even the net price? Is it an effective drug? What's the right price to be paying for this drug? Should be the operative question, right? Just like what's the quality and appropriateness of any medical service? Maybe we should just quit it and just pay for value. And with that, let me introduce Sarah Emond, CEO of ICER (Institute for Clinical and Economic Review), and I will let Sarah tell the rest of the story. Also mentioned in this episode are Institute for Clinical and Economic Review (ICER); Cora Opsahl; 32 BJ Health Fund; Payerset; Aventria Health Group; Dea Belazi, PharmD, MPH; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here.   You can learn more at ICER.org and follow Sarah on LinkedIn.   Sarah K. Emond, MPP, is president and chief executive officer of the Institute for Clinical and Economic Review (ICER), a leading nonprofit health policy research organization, with 25 years of experience in the business and policy of healthcare. She joined ICER in 2009 as its first chief operating officer and third employee and has worked to grow the organization's approach, scope, and impact over the years. Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston. A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor's degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based healthcare.   02:28 What is ICER? 02:47 What does the Institute for Clinical and Economic Review do? 05:09 The importance of still showing up, even when others don't understand or disagree. 06:51 EP293 ("Game Theory Gone Wild") with Dea Belazi, PharmD, MPH. 09:04 Why it's important to think about population health and how our choices impact affordability for everyone.   You can learn more at ICER.org and follow Sarah on LinkedIn.   @sarahkemond discusses #ICER and the status quo of #pharmaceuticaldrug #pricing on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW43), Olivia Ross (Take Two: EP240), John Quinn, Dr Sam Flanders and Shane Cerone (EP492), Elizabeth Mitchell (EP491), Shane Cerone and Dr Sam Flanders (Part 1), Dan Greenleaf (Part 2), Dan Greenleaf (Part 1), Mark Cuban and Cora Opsahl  

I was out drinking martinis with Cora Opsahl, director of 32BJ Health Fund, and Cora said, "Look, most plan sponsors' biggest expense is health system spend, hospital spend." I know this is an unexpected start to an episode about pharmaceutical pricing and value featuring Sarah Emond, CEO of ICER (Institute for Clinical and Economic Review). But yeah, 50% of most plan sponsors' spend these days goes to health systems. Fifty percent! One half! For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. So, if a patient who is adherent to a drug and that drug keeps that patient out of the hospital, why do I want to make a patient have excessive skin in the game to get that drug, which everybody knows at this point this "skin in the game" can cause said patient to not be adherent in many cases, cost being a very big reason patients give for not taking medications as prescribed. So then we have this not adherent patient who winds up in the hospital, via the ER often enough. The core issue here that surfaced, bottom line—and I'm not sure if this was in spite of the martinis or as a result of them—but while hospital spend is the largest health expense, high-value drugs that prevent hospitalization often face patient cost sharing and access restrictions, which leads to poor patient adherence and ultimately higher system cost potentially. So then Cora and I spent the next half hour debating when the statement is empirically true and when it's not. And you know what it all boils down to? What's the value of the drug? Do we even know what that means to start? But if it's determined that the drug is relatively high value, then the plan desperately should want to do everything possible to keep that patient on that medication, and cost sharing is a huge barrier to adherence. Today, as I said, I'm speaking with Sarah Emond, CEO over at ICER, and we get into all of this in the conversation that follows. In fact, most of the conversation that follows explores the tensions that exist in the current way that we sell and buy pharmaceutical products. I'm just gonna sum up these tensions in a list here at the top of this show. There's six of them that Sarah Emond and I discussed today by my counting, and each of these we explore in some depth. So, here's the list. Tension 1: The value of any given drug (in other words, what is the fair price for that drug considering the health gains that it delivers) versus the total cost to the plan for the total population taking that drug. GLP-1s have entered the chat. GLP-1s (by ICER's analysis, at least) are super high-value drugs that also can bankrupt plans due to the number of folks who may benefit from taking the drug. Definitely a tense tension to kick off our list here. Tension 2: The list or net price of a drug versus patient access and affordability. Again, this can be tense in an area of much misalignment. You can have a great well-priced drug with huge patient affordability and access challenges because drug net price and coinsurance amounts often have nothing to do with each other. Tension 3: Lifetime value of a drug versus a 3-, 2.5-year, whatever time horizon that many plan sponsor actuaries use in their value assessment. We discussed this today, but there's a Summer Short (SUMS7) on actuarial value horizons with Keith Passwater and JR Clark if you wanna dig in on this further. Tension 4: The tension between the societal value of a drug or even the patient's perceived value of a drug versus what an employer plan sponsor might perceive as the value. What is the formula used to determine value? What's in and what's out? So, that's a bigger conversation just beyond the time horizon for what's included in this calculation. Tension 5: Exacerbating the what's included in the value contemplation beyond just what you include in there is the tension between what is hypothetically of value and what is possible to measure. If you have pharma datasets and medical datasets separate in silos, who knows how many hospital readmissions were prevented by whatever drug? And how much presenteeism or absenteeism exists. I mean, it is an outlier, again, if anyone even knows the net price they paid for a drug, just to level set context here. Tension 6: Lowering financial barriers for patients to take drugs that are of value versus status quo goals and incentives. Like, for example, PBMs (pharmacy benefit managers) are often told that their goal is to reduce drug spend. Okay … so, how do I do that? Oh, reduce access either by prior auths or delay tactics or really high coinsurance, which is gonna reduce adherence by design. And it's someone else's problem—if I'm just thinking like a status quo PBM—if medical spend goes up, right? So, that's our last and not insignificant tension. And look, who comes out the loser in all of these tensions when they get tense? Patients. Not pricing based on value and not buying and setting up cost sharing based on value punishes patients and also plan sponsors or any other ultimate purchaser in the long term, given that the plan is but a population of patients if you start thinking about it in that context. Here is Sarah's advice in a nutshell: Pharma, sell. Pick your price based on something other than market power. And some pharma companies are actually dipping their toe into these waters and doing it. But then PBMs and plan sponsors have to hold up their end of the bargain here and buy drugs based on their value, not just the size of their rebates or some other discounting promise. And then we gotta continue the through line through to member affordability and access. High-value drugs should get preferred. So, right, do a high-value formulary. Listen to the show with Nina Lathia, RPh, MSc, PhD (EP426) on high-value formularies and then listen (after you're done with that one) to episode 435 with Dan Mendelson entitled "Optimized Pharmacy Benefits Are Required if You Want to Do or Buy Value-Based Care." Also, as I said, GLP-1s come up in this conversation, so … yeah, buckle up. One last thing, besides my normal thank you to Aventria Health Group for sponsoring this episode, I am so pleased to thank Payerset for donating to help Relentless Health Value stay on the air. Payerset is a price transparency company with a mission to create fair and equitable healthcare for everyone. Love that. Payerset empowers healthcare organizations, employers, and patients with the most complete set of healthcare price transparency data. They benchmark every negotiated rate and claim and delivering the actionable insights needed for smarter contract negotiations and a more transparent healthcare system. As I have said several times today, my conversation is with Sarah Emond, CEO of ICER. Also mentioned in this episode are Institute for Clinical and Economic Review (ICER); Cora Opsahl; 32 BJ Health Fund; Keith Passwater; JR Clark; Nina Lathia, RPh, MSc, PhD; Dan Mendelson; Aventria Health Group; Payerset; Antonio Ciaccia; Elizabeth Mitchell; Purchaser Business Group on Health (PBGH); Shane Cerone; Sam Flanders, MD; Mark Cuban; Morgan Health; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here. You can learn more at ICER.org and follow Sarah on LinkedIn.   Sarah K. Emond, MPP, is president and chief executive officer of the Institute for Clinical and Economic Review (ICER), a leading nonprofit health policy research organization, with 25 years of experience in the business and policy of healthcare. She joined ICER in 2009 as its first chief operating officer and third employee and has worked to grow the organization's approach, scope, and impact over the years. Prior to joining ICER, Sarah spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company and several years with a healthcare communications firm. Sarah began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston. A graduate of the Heller School for Social Policy and Management at Brandeis University, Sarah holds a Master of Public Policy degree with a concentration in health policy. Sarah also received a bachelor's degree in biological sciences from Smith College. Sarah speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based healthcare.   08:18 Why list prices are a lie. 10:59 How does the rebate model sometimes get in the way of paying for value? 12:50 Bonus clip with Sarah Emond. 13:14 EP491 with Elizabeth Mitchell. 13:20 EP490 and EP492 with Shane Cerone and Sam Flanders, MD. 14:37 The tension that is created between affordability and adherence. 15:03 When cost sharing makes sense in pharmaceutical drug pricing. 17:26 INBW42 with Stacey on moral hazard. 18:53 How GLP-1s are "wildly cost effective." 21:32 Why the sticker shock on cost-effective drugs is a failure in the system for paying for value. 22:38 ICER's report on GLP-1s. 26:59 EP385 with Dan Mendelson. 28:57 How employers and payers can have a value assessment approach and a health insurance system that allows access to cost-effective drugs. 29:48 How cost-effective prices are calculated. 31:55 One of the core value underpinnings for value assessment of drugs. 34:54 Why manufacturers and pharmacy benefit managers should work together more by referencing something like an ICER report. 36:55 EP426 with Nina Lathia, RPh, MSc, PhD. 38:21 "We can make different choices."   You can learn more at ICER.org and follow Sarah on LinkedIn.   @sarahkemond discusses #pharmaceutical #drugpricing on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Stacey Richter (INBW43), Olivia Ross (Take Two: EP240), John Quinn, Dr Sam Flanders and Shane Cerone (EP492), Elizabeth Mitchell (EP491), Shane Cerone and Dr Sam Flanders (Part 1), Dan Greenleaf (Part 2), Dan Greenleaf (Part 1), Mark Cuban and Cora Opsahl

Why have we lost our trust in natural medicine? In this video, we'll discuss why natural medicine is ignored and sometimes even dismissed as folklore. Is it wise to invalidate the wisdom of the past? Discover the truth about natural medicine in this video.0:00 Introduction: Natural medicine suppression0:19 United States Dispensatory 0:38 Pharmaceutical vs. natural medicine 3:08 The advancement of medicine 6:35 Natural remedies of the past The “United States Dispensatory” by Wood and Lawall may provide insight into alternative medicine censorship in the United States. The 21st edition, published in 1926, was the most authoritative and comprehensive reference for American medicine. At the time of publication, 75% of medicine consisted of various natural remedies, while only 25% consisted of synthetic compounds.Since then, there's been a gradual transition from natural remedies to synthetic drugs. When the 22nd edition of the book was published in 1943, the ratio of natural to synthetic drugs shifted to 50:50.Today, medicine is often prescribed without considering lifestyle, eating habits, sleep patterns, stress levels, or the microbiome. Symptoms of the underlying problems are treated without addressing the root cause.Discover these 20 natural remedies that have stood the test of time, along with the ailment they have historically been used to address.1. Cod liver oil—Tuberculosis, tetany, nerve pain2. Nutmeg oil—Psychotic problems3. Olive oil—Mild laxative, gallstones 4. Pine needle oil—Eliminates mucus from the lungs 5. Castor oil—Mild laxative 6. Sandalwood oil—Gonorrhea, bronchitis, bladder infections 7. Sassafras oil—Antiseptic 8. Betaine hydrochloride—Indigestion, gastric problems9. Pepsin—Digestive issues 10. Lugol's iodine—Thyroid support and protection 11. Magnesium sulfate—Sleep support, anxiety, pain killer 12. Calcium chloride—Acidifies the body 13. Liver extract—Anemia 14. Methylene blue—Shrinks tumors, meningitis, bladder infections, gonorrhea, and supports the mitochondria15. Lithium carbonate—Relaxation, anxiety, and depression relief16. Glauber's salt—Laxative17. Vitamin D—Autoimmune conditions18. Colloidal silver19. Activated charcoal—Food poisoning, gas20. Niacin—Lowers triglycerides, increases HDL, increases lifespan, supports cardiovascular health, acts as a NAD precursorDr. Eric Berg DC Bio:Dr. Berg, age 60, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the Director of Dr. Berg Nutritionals and author of the best-selling book The Healthy Keto Plan. He no longer practices, but focuses on health education through social media.Disclaimer: Dr. Eric Berg received his Doctor of Chiropractic degree from Palmer College of Chiropractic in 1988. His use of “doctor” or “Dr.” in relation to himself solely refers to that degree. Dr. Berg is a licensed chiropractor in Virginia, California, and Louisiana, but he no longer practices chiropractic in any state and does not see patients, so he can focus on educating people as a full-time activity, yet he maintains an active license. This video is for general informational purposes only. It should not be used to self-diagnose, and it is not a substitute for a medical exam, cure, treatment, diagnosis, prescription, or recommendation. It does not create a doctor-patient relationship between Dr. Berg and you. You should not make any change in your health regimen or diet before first consulting a physician and obtaining a medical exam, diagnosis, and recommendation. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.

“VO2 max is the best predictor of lifespan,” says Peter Attia, M.D. Peter Attia, M.D., physician, founder of Early Medical, and expert in the applied science of longevity, joins us today to break down the key levers for extending both lifespan and healthspan—from how to train for a higher VO2 max to the biomarkers that truly predict long-term health. - The most powerful habit for longevity (~6:15) - VO2 max (~8:55) - How to increase your VO2 max (~10:08) - Heart rate vs. perceived exertion (~12:35) - Attia's strength training routine (~15:20) - 2 exercises Attia stopped doing (17:00) - Diminishing returns in terms of exercise (~19:55) - His take on wearables (~21:25) - Cardiovascular disease markers (~23:38) - Lowering ApoB (~25:35) - Pharmaceutical interventions for LDL & ApoB (~27:50) - Neuroinflammation markers (~37:25) - Perspectives on statins (~40:45) - The role of nutrition (~42:50) - Potential benefits of GLP-1s (~45:00) - Peptides (~47:50) - The power of exercise (~51:00) Referenced in the episode:  - Follow Attia on Instagram (@peterattiamd) - Listen to his podcast, The Peter Attia Drive  - Check out his website (https://peterattiamd.com/)  - Pick up his book, Outlive: The Science of Art & Longevity  - Take his class on MasterClass (https://www.masterclass.com/series/science-for-a-longer-better-life) - Watch the trailer for his class on MasterClass (youtube.com/watch?v=f_Mz095swls&feature=youtu.be)   We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices